Public health charities are under intense pressure from potential or ongoing commercial sponsors to boost their budgets with product promotion schemes. For example, the American Diabetes Association (ADA) currently has a $1.5 million sponsorship deal with Cadbury Schweppes, maker of Dr. Pepper and the Cadbury Creme egg.
On November 17 the U.S. Food and Drug Administration (FDA) approved silicone breast implants manufactured by Mentor Corporation and Allergan. PR Week reports that the PR firm MS&L "began working with Inamed Corp.
Negotiators representing Big Pharma and the U.S. Food and Drug Administration are close to a deal on raising fees paid by industry to speed up reviews of direct-to-consumer advertising. A spokesperson for the trade group BioCentury said that the FDA is seeking to raise about $6.2 million per year, putting individual application review fees at about $41,000.
The drug industry is bracing itself for major legislative changes once the new Congress sits. Forbes journalist Matthew Herper notes that, following the mid-term elections, major drug company shares have dropped by over 5%.
US Deputy Health Secretary, Alex Azar, is lobbying the Britain's Health Secretary, Patricia Hewitt, to ease restrictions on the drug industry. In particular, the U.S. drug companies want the ban on direct-to-consumer advertising dropped and to increase the prices the government pays for drugs.
Even though the European Medicines Agency has endorsed the use of Prozac and similar drugs in children over eight, medical researchers doubt the appropriateness of prescribing such powerful drugs in all but rare cases.
Alan Cassels notes that disease mongering advertisements for cholesterol-lowering drugs, such as for Pfizer's Lipitor, hype the risk of heart attacks for those people with 'high' cholesterol.